The molecular features that define clear cell renal cell carcinoma (ccRCC) initiation and
progression are being increasingly defined. The TRACERx Renal studies and others that …

Insights into the role of the tumor suppressor pVHL in oxygen sensing motivated the testing
of drugs that target the transcription factor HIF or HIF-responsive growth factors, such as …

Background Patients with radioiodine-refractory differentiated thyroid cancer (DTC)
previously treated with vascular endothelial growth factor receptor (VEGFR)-targeted …

Background Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth
factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of …

Angiogenesis is a hallmark of cancer and is required for tumor growth and progression.
Antiangiogenic therapy has been revolutionarily developing and was approved for the …

Renal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and
accounts for> 90% of cancers in the kidney. The disease encompasses> 10 histological and …

Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned
from a nonspecific immune approach (in the cytokine era), to targeted therapy against …

Kidney cancers have been extensively studied, and insights from an increased
understanding of tumor biology have led to increases in survival rates. Therapies aimed at …

Purpose Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor
receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell …

Background Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR,
and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of …